Business Context and Reporting Period
Company: DiaMedica Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 26, 2021
Reporting Period: Event date of September 26, 2021.
Business Context: The Company, a clinical-stage biopharmaceutical company, entered into a material definitive agreement for a private placement of equity securities to fund clinical development and working capital.
Key Financial Metrics
Capital Raise Details:
- Shares Issued: 7,653,060 common shares.
- Purchase Price: $3.92 per share (equal to the closing sale price on September 24, 2021).
- Gross Proceeds: Approximately $30 million (before fees and expenses).
- Investors: Ten accredited investors.
- Continuation of clinical development and product activities for DM199.
- Support for the recently initiated pivotal ReMEDy2 trial.
- Working capital and general corporate purposes.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity ratios as this is a transactional report rather than a periodic financial statement.
Material Changes
This filing reports a material change in the Company's capital structure through the entry into a Securities Purchase Agreement. The Company agreed to issue new common shares in a private placement exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The closing of the transaction was expected to occur on or about September 28, 2021, subject to customary conditions.
Guidance, Outlook, and Risks
Management Commentary: Management intends to utilize the net proceeds to advance the pivotal ReMEDy2 trial for DM199 and maintain operational liquidity.
Registration Rights: The Company agreed to file a resale registration statement within 10 business days of closing and use commercially reasonable best efforts to have it declared effective within 30 calendar days (or 75 days in the event of a full review).
Risks and Contingencies:
- Liquidated Damages: If the Company fails to meet specified filing deadlines or keep the registration statement effective, it may be required to pay liquidated damages to the Purchasers.
- Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions.
Investor Verification Checklist
- Verify the actual closing date of the Private Placement (expected September 28, 2021) and confirm receipt of gross proceeds.
- Review the final net proceeds after deducting fees and offering expenses.
- Monitor the filing and effectiveness status of the Resale Registration Statement to ensure compliance with the 30-day/75-day deadlines.
- Confirm the specific allocation of funds to the ReMEDy2 trial versus general working capital in subsequent reports.
- Check for any subsequent filings regarding liquidated damages or delays in the registration process.